×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:ATHA

Athira Pharma Earnings Date, Estimates & Call Transcripts (2022)

$2.74
-0.01 (-0.36%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.65
$2.83
50-Day Range
$2.74
$11.78
52-Week Range
$2.53
$16.65
Volume
2.48 million shs
Average Volume
1.55 million shs
Market Capitalization
$103.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.60

Earnings Summary

Upcoming
Earnings Date
Aug. 15Estimated
Actual EPS
(May. 12)
-$0.56 Missed By -$0.01
Consensus EPS
(May. 12)
-$0.55
Skip Charts & View Estimated and Actual Earnings Data

ATHA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ATHA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Athira Pharma Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.73)($0.73)($0.73)
Q2 20221($0.90)($0.90)($0.90)
Q3 20221($1.03)($1.03)($1.03)
Q4 20221($1.17)($1.17)($1.17)
FY 20224($3.83)($3.83)($3.83)
Q1 20231($0.88)($0.88)($0.88)
Q2 20231($0.95)($0.95)($0.95)
Q3 20231($1.19)($1.19)($1.19)
Q4 20231($1.52)($1.52)($1.52)
FY 20234($4.54)($4.54)($4.54)

ATHA Earnings Date and Information

Athira Pharma last issued its quarterly earnings results on May 12th, 2022. The reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. Athira Pharma has generated ($1.73) earnings per share over the last year (($1.73) diluted earnings per share). Earnings for Athira Pharma are expected to decrease in the coming year, from ($2.67) to ($3.44) per share. Athira Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 15th, 2022 based off prior year's report dates.

Athira Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/15/2022
(Estimated)
        
5/12/20223/31/2022($0.55)($0.56)($0.01)    
3/24/2022Q4 2021($0.61)($0.37)+$0.24($0.37)    
11/9/20219/30/2021($0.50)($0.42)+$0.08($0.42)
8/15/20216/30/2021($0.35)($0.38)($0.03)($0.38)
5/12/20213/31/2021($0.30)($0.25)+$0.05($0.25)
3/24/202112/31/2020($0.40)$0.71+$1.11($0.24)
11/17/20209/30/2020($0.25)($1.12)($0.87)($1.12)  












Athira Pharma Earnings - Frequently Asked Questions

When is Athira Pharma's earnings date?

Athira Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 15th, 2022 based off last year's report dates. Learn more on ATHA's earnings history.

Did Athira Pharma beat their earnings estimates last quarter?

In the previous quarter, Athira Pharma (NASDAQ:ATHA) missed the analysts' consensus estimate of ($0.55) by $0.01 with a reported earnings per share (EPS) of ($0.56). Learn more on analysts' earnings estimate vs. ATHA's actual earnings.

How can I listen to Athira Pharma's earnings conference call?

The conference call for Athira Pharma's latest earnings report can be listened to online. Listen to Conference Call

How can I read Athira Pharma's conference call transcript?

The conference call transcript for Athira Pharma's latest earnings report can be read online. Read Transcript

How much profit does Athira Pharma generate each year?

Athira Pharma (NASDAQ:ATHA) has a recorded net income of -$54.85 million. ATHA has generated -$1.73 earnings per share over the last four quarters.

What is Athira Pharma's EPS forecast for next year?

Athira Pharma's earnings are expected to decrease from ($2.67) per share to ($3.44) per share in the next year.

This page (NASDAQ:ATHA) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.